Manuka Honey in Your Sinus Rinse: What the Research Shows

Walk into any health food store and you'll find manuka honey positioned near the vitamins, marketed for everything from wound care to gut health to sinus relief. But is adding manuka honey to your nasal rinse actually backed by science — or is it another wellness trend that outpaces the evidence?

The answer is more nuanced than either enthusiasts or skeptics admit. There is real, peer-reviewed clinical research on manuka honey sinus irrigation. Some of it is genuinely encouraging. Some of it is a reality check. And almost all of the mainstream articles on this topic fail to accurately represent what the studies actually found.

This article reviews the full body of evidence — including the clinical trials most websites ignore — so you can make an informed decision about whether a manuka honey sinus rinse belongs in your protocol.

What Makes Manuka Honey Different From Regular Honey?

Regular honey has been known for its antimicrobial properties since antiquity. The antibacterial activity of most honeys comes primarily from hydrogen peroxide produced by the enzyme glucose oxidase. Manuka honey — produced from the nectar of Leptospermum scoparium, a flowering shrub native to New Zealand and southeastern Australia — is different.

What sets manuka apart is exceptionally high levels of methylglyoxal (MGO), a naturally occurring compound derived from the precursor dihydroxyacetone (DHA) found in manuka flower nectar. MGO is a potent antibacterial agent that works through a different mechanism than hydrogen peroxide — and critically, it does not break down under the conditions that inactivate peroxide-based honeys (such as body temperature, dilution, or enzyme exposure).

This stability is what makes manuka honey particularly interesting for sinus use, where the rinse solution is inevitably diluted by mucus and body fluids. The antibacterial activity persists even in diluted form.

Understanding UMF and MGO Ratings

Two grading systems are used to quantify manuka honey potency:

• UMF (Unique Manuka Factor): A licensed quality trademark that certifies levels of MGO plus two additional chemical markers — leptosperin and DHA — that verify authentic manuka origin. UMF 10+ is considered entry-level therapeutic; UMF 20+ and above is used in clinical research.
• MGO rating: Directly measures methylglyoxal concentration in mg/kg. MGO 263+ ≈ UMF 10+; MGO 550+ ≈ UMF 16+; MGO 800+ ≈ UMF 20+.

The research reviewed below generally uses high-potency manuka honey (UMF 20+ equivalent or MGO augmented to 1,300 mg/kg) to maximize the antibacterial signal. Consumer-grade manuka honey with lower ratings may produce weaker effects.

Why Chronic Rhinosinusitis Is So Hard to Treat

To understand why researchers are exploring manuka honey as a sinus treatment at all, you need to understand the core problem in chronic rhinosinusitis (CRS): bacterial biofilms.

Biofilms are structured communities of bacteria encased in a self-produced matrix of sugars and proteins. In this protected state, bacteria are up to 1,000 times more resistant to antibiotics than the same bacteria in a free-floating (planktonic) state. Standard cultures often miss biofilm-producing organisms, leading to repeated antibiotic courses that treat the wrong target.

Research published in Laryngoscope found that bacterial biofilms are present on the mucosal surfaces of 75% of patients with CRS, compared to fewer than 5% of controls with healthy sinuses. This biofilm burden correlates directly with worse symptom scores, higher rates of recurrence after surgery, and reduced response to conventional therapies.

This is where manuka honey becomes interesting: unlike many antibiotics, MGO has demonstrated activity against biofilm-forming bacteria in laboratory conditions — particularly Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, and Streptococcus pneumoniae — all three of which are among the most common bacterial culprits in CRS.

The Clinical Evidence: What Human Trials Have Found

The Phase 1 Randomized Controlled Trial (2019)

The most rigorous study to date on manuka honey sinus irrigation was published in the International Forum of Allergy and Rhinology in 2019. This was a phase 1 randomized, single-blinded, placebo-controlled trial that enrolled patients with recalcitrant chronic rhinosinusitis — meaning patients who had already failed standard medical and surgical treatments.

This result is important to understand accurately. Many pro-manuka websites cite this study as "evidence that manuka honey works for sinuses" — which is technically true but incomplete. What the study actually shows is that manuka honey performs roughly equivalently to a targeted course of antibiotics in some of the most treatment-resistant CRS patients. For an antibiotic-free, naturally derived substance, that is a genuinely impressive outcome. But it is not a "cure."

The Pilot Study vs. Standard Saline (2021)

A second important study, published in the International Forum of Allergy and Rhinology in 2021 (PMC7895450), compared manuka honey irrigations directly to standard saline irrigations in CRS patients with prior sinus surgery. This was a smaller pilot study designed to generate preliminary data for a larger trial.

The gap between "clinically important improvement" and "statistically significant" is crucial to understand: it means patients felt meaningfully better (by a margin that would matter to a doctor making treatment decisions), but the sample was too small to rule out chance. The signal is there — the evidence base just needs to grow.

The Cystic Fibrosis Pilot Study (NHS, 2022)

A 2022 pilot study registered with the NHS Health Research Authority explored manuka honey sinus rinses specifically in cystic fibrosis patients — a population with notoriously difficult chronic sinus disease and high rates of antibiotic-resistant infections. The study used a manuka honey/saline mixture and measured sino-nasal outcome test (SNOT) scores over time.

Cystic fibrosis patients are a particularly relevant population because their sinuses frequently harbor Pseudomonas aeruginosa in biofilm form — one of the organisms that manuka honey has shown in vitro activity against. The results of this study remain under peer review at time of writing.

The Allergic Fungal Rhinosinusitis Case Series (St. Paul's Sinus Centre)

Researchers at St. Paul's Sinus Centre in Vancouver conducted a case series evaluating manuka honey irrigation in patients with allergic fungal rhinosinusitis (AFRS) — a form of CRS driven by fungal biofilm rather than bacterial. Two patients who had failed maximal medical management were treated with manuka honey irrigation for a 12-week period.

Both patients showed endoscopic improvement and symptom reduction. This is a very small sample, but it raises an interesting question: does manuka honey's non-antibiotic mechanism give it an advantage in cases where bacteria are not the primary driver? Larger trials are needed to answer this.

What Manuka Honey Does to Biofilms (The Lab Evidence)

While the human clinical evidence is still developing, the in vitro (laboratory) data is more definitive. Multiple studies have demonstrated that manuka honey disrupts biofilm formation and penetrates established biofilms in ways that standard antibiotics cannot.

• At concentrations of 5-12.5%, manuka honey inhibits Staphylococcus aureus (including MRSA) in laboratory cultures — concentrations achievable in a 16.5% rinse solution after dilution by nasal mucus
• MGO at 1.3 mg/mL has demonstrated activity against Pseudomonas aeruginosa biofilms in vitro
• Unlike antibiotics, which typically target single bacterial pathways (creating selective pressure for resistance), MGO acts through multiple simultaneous mechanisms — making bacterial adaptation significantly less likely
• Manuka honey's low pH (approximately 3.5-4.5) contributes additional antibacterial activity independent of MGO content

This is the laboratory foundation that motivates continued clinical research. The mechanisms are real. The question is whether those mechanisms translate to clinically meaningful improvements in humans at achievable rinse concentrations.

How to Add Manuka Honey to Your Sinus Rinse: A Practical Protocol

If you want to experiment with manuka honey nasal irrigation based on the current evidence, here is how to do it safely and in line with published protocols.

Ingredients

• 1 ATO Health sinus rinse packet (provides the correct pharmaceutical-grade saline base)
• 240 mL (8 oz) distilled or sterile water, warmed to body temperature
• 1 teaspoon (approximately 5 mL) high-grade manuka honey (UMF 20+ or MGO 800+)

Preparation

1. Warm your distilled water to approximately 98–100°F (37°C). Warmer water helps dissolve the honey and is more comfortable for nasal use.
2. Dissolve the manuka honey in the warm water first, stirring until fully incorporated. Honey in cold water forms sticky clumps that may not distribute evenly in the rinse.
3. Add the contents of one ATO Health saline packet. The buffered saline mixture maintains the correct osmolality and pH for nasal comfort.
4. Pour into a clean neti pot or squeeze bottle and rinse as normal — see our ENT tips guide for proper technique.
5. Rinse your irrigation device thoroughly after use. Honey residue is a potential food source for bacteria — clean your bottle with hot soapy water or follow your regular cleaning protocol.

Frequency and Duration

The published clinical trials used twice-daily rinses for 14-day periods. This is a reasonable starting protocol for acute flare-ups or post-surgical recovery. For general maintenance, once-daily manuka honey rinsing a few times per week is a more sustainable approach.

Who Is Most Likely to Benefit?

Based on the current evidence, manuka honey sinus rinses are most likely to provide meaningful benefit for:

• Chronic rhinosinusitis patients who haven't responded to antibiotics: The biofilm-disrupting mechanism of MGO works differently from conventional antibiotics, making it potentially valuable in treatment-resistant cases
• Post-FESS (functional endoscopic sinus surgery) recovery: Several studies evaluated manuka honey in post-surgical patients, where the opened sinus cavities allow better irrigation penetration and the risk of re-colonization is high — see our post-surgery irrigation guide
• Patients with recurrent acute sinusitis: Regular irrigation with a bioactive rinse may help prevent the biofilm re-establishment that drives recurrent infections
• People seeking to reduce antibiotic use: Given the growing evidence linking antibiotic use to disruption of the nasal microbiome, a non-antibiotic antimicrobial adjunct is genuinely appealing for mild-to-moderate cases

For straightforward seasonal allergies, standard saline rinses are well-established, inexpensive, and have a stronger evidence base. Manuka honey likely adds marginal benefit for this population over a well-performed regular rinse.

Common Misconceptions About Manuka Honey and Sinuses

Misconception 1: "Any manuka honey works"

This is false. Most consumer-grade manuka honeys have MGO concentrations far below what has been used in clinical trials. You need UMF 15+ (MGO 514+) at minimum for meaningful therapeutic activity. Check for the UMF trademark and a batch-specific test certificate when purchasing.

Misconception 2: "Eating manuka honey will fix your sinuses"

Oral consumption of manuka honey does not deliver MGO to your sinus mucosa at therapeutically relevant concentrations. The active compounds are metabolized in the GI tract before they could reach your sinuses. Direct nasal application is required for the mechanism studied in clinical trials.

Misconception 3: "Clinical trials proved manuka honey cures CRS"

No clinical trial has reached this conclusion. The 2019 phase 1 trial found manuka honey was "safe but not superior" to antibiotic therapy in recalcitrant CRS — meaning it performed at a similar level to antibiotics in a difficult patient population, which is encouraging but not a cure claim.

Misconception 4: "Manuka honey can replace your regular saline rinse"

High-volume saline irrigation provides mechanical clearance of mucus, biofilm debris, allergens, and crusting that manuka honey alone cannot replicate. The most rational approach is to use manuka honey alongside a proper saline rinse — not instead of it. Regular saline rinsing has its own strong evidence base that stands independently.

What the Research Doesn't Yet Tell Us

Several critical questions remain unanswered by the current evidence base:

• Optimal concentration and UMF grade: The 16.5% concentration used in the main clinical trial is relatively high. Whether lower concentrations (which are easier to prepare and cheaper) produce equivalent outcomes is unknown.
• Long-term safety of regular use: Phase 1 trials only establish 14-day safety. The effects of daily or near-daily use over months or years have not been formally studied.
• Whether the nasal microbiome is affected: Manuka honey's broad-spectrum antibacterial activity raises theoretical concerns about disrupting beneficial nasal bacteria — a question the trials have not systematically addressed. Our article on the nasal microbiome covers why this matters.
• Head-to-head comparison with other biofilm agents: How does manuka honey compare to other studied biofilm-disrupting rinse additives like baby shampoo or xylitol? No direct comparison trials have been published.

Frequently Asked Questions

Does manuka honey help with sinus infections?

Laboratory research shows manuka honey has strong antibacterial activity against common sinus pathogens including MRSA and Staphylococcus aureus, due to its high methylglyoxal (MGO) content. However, clinical trials in humans show mixed results — it appears safe and may provide symptom relief, but has not consistently outperformed standard saline rinses alone in randomized controlled trials.

What concentration of manuka honey is used in sinus rinses?

Clinical trials have used concentrations ranging from 16.5% manuka honey in saline (the most studied protocol) down to approximately 5% for milder rinses. Higher UMF ratings (UMF 20+ or MGO 800+) are generally recommended for therapeutic purposes.

Is manuka honey safe to put in your nose?

Phase 1 clinical trials have found manuka honey nasal irrigations to be well-tolerated with high retention rates. The main precaution is ensuring you dissolve it in sterile or distilled water — never tap water. People with honey or bee product allergies should not use it. Always consult your ENT before adding it to your regimen.

What is the best manuka honey for sinus rinse?

Look for medical-grade or food-grade manuka honey with a UMF rating of 15+ or MGO 550+ for sinus use. The UMF and MGO numbers are what drive the antibacterial activity — generic honey does not contain sufficient methylglyoxal to replicate the effects studied in clinical trials.

Can I mix manuka honey with my regular sinus rinse packets?

Yes — some protocols involve dissolving a small amount of manuka honey (approximately 1 teaspoon per 240 mL of rinse solution) along with your regular premixed saline packet in distilled or sterile water. The saline packet provides the correct salt-to-water ratio for nasal comfort, while the honey adds its biofilm-disrupting and antibacterial properties.